28.03.2016, 11:06
Asahi Kasei Pharma Corp. and PeptiDream Inc. have concluded a joint R&D agreement
OREANDA-NEWS. Asahi Kasei Pharma Corp. (Head office: Chiyoda-ku, Tokyo, Japan; President: Kazuyoshi Hori) and PeptiDream Inc. (Head office: Meguro-ku, Tokyo, Japan; CEO: Kiichi Kubota) have concluded a joint R&D agreement for the discovery and development of nonstandard peptides against multiple drug target molecules.
PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) enables the rapid artificial generation of nonstandard peptide libraries with unparalleled diversity, and the efficient identification of nonstandard peptides that hold potential as therapeutics against target molecules by high-speed screening.
Under the terms of this agreement, Asahi Kasei Pharma will incorporate nonstandard peptide drug-discovery technology using PDPS in next-generation drug research. It is expected that this will dramatically increase the possibility of discovering candidate drug molecules for future development.
About PeptiDream Inc.
Founded in July 2006, PeptiDream is a biopharmaceutical company with world-leading technology for the discovery and development of novel highly functional peptide therapeutics. Based on its core technology of PDPS, PeptiDream operates businesses specialized in the discovery and development of highly functional peptide therapeutics, and promotes R&D by collaborating with other pharmaceutical companies all over the world. PeptiDream holds exclusive rights for PDPS-related patents.
PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) enables the rapid artificial generation of nonstandard peptide libraries with unparalleled diversity, and the efficient identification of nonstandard peptides that hold potential as therapeutics against target molecules by high-speed screening.
Under the terms of this agreement, Asahi Kasei Pharma will incorporate nonstandard peptide drug-discovery technology using PDPS in next-generation drug research. It is expected that this will dramatically increase the possibility of discovering candidate drug molecules for future development.
About PeptiDream Inc.
Founded in July 2006, PeptiDream is a biopharmaceutical company with world-leading technology for the discovery and development of novel highly functional peptide therapeutics. Based on its core technology of PDPS, PeptiDream operates businesses specialized in the discovery and development of highly functional peptide therapeutics, and promotes R&D by collaborating with other pharmaceutical companies all over the world. PeptiDream holds exclusive rights for PDPS-related patents.
Комментарии